What this means
Postoperative cognitive dysfunction (POCD) is a frequent neurological complication in older surgical patients, leading to substantial declines in quality of life and placing a considerable burden on society. This review provides a comprehensive overview of how mitochondrial dysfunction contributes to POCD, including disrupted energy metabolism, excessive reactive oxygen species production, calcium imbalance, and abnormalities in mitochondrial dynamics and quality control processes.
A plain-English summary is on its way. Until then, this is the start of the authors' own summary.
- Who it was tested in
- People
- Kind of research
- A summary of earlier studies
The science
- Original title
- Targeting Mitochondria for Postoperative Cognitive Dysfunction: From Mechanisms to Therapeutics.
- Authors
- Zhang A, Zhao A, Fan G et al.
- Journal
- Molecular neurobiology
- Published
- Aug 8, 2026
- Study type
- Review · in humans
- PMID
- 42570043 ↗
Abstract
Postoperative cognitive dysfunction (POCD) is a frequent neurological complication in older surgical patients, leading to substantial declines in quality of life and placing a considerable burden on society. This review provides a comprehensive overview of how mitochondrial dysfunction contributes to POCD, including disrupted energy metabolism, excessive reactive oxygen species production, calcium imbalance, and abnormalities in mitochondrial dynamics and quality control processes. These mitochondrial impairments further trigger neuroinflammation and activate multiple cell death pathways. In addition, the review examines current mitochondria-targeted therapeutic strategies and their underlying mechanisms, highlighting the neuroprotective roles of agents such as SS-31, Mdivi-1, P110, and NLRP3 inhibitors in preclinical studies. It also explores the promise of multi-target combinational treatments, time-specific interventions, and individualized therapeutic approaches. Finally, the review discusses key barriers to clinical translation such as limited blood-brain barrier permeability, unintended drug effects, and altered pharmacokinetics in the elderly and considers emerging technologies, including nanocarrier drug-delivery systems and AI-guided personalized treatment plans, as potential tools for achieving more precise prevention and management of POCD.
Zhang A, Zhao A, Fan G et al. Targeting Mitochondria for Postoperative Cognitive Dysfunction: From Mechanisms to Therapeutics. Molecular neurobiology. 2026. doi:10.1007/s12035-026-06120-3. PMID: 42570043. https://pubmed.ncbi.nlm.nih.gov/42570043/
Related research
The Role of Oxidative Stress in Heart Failure: Mechanisms and Therapeutic Targets.
Heart failure is characterised by increased production of reactive oxygen species (ROS), which contribute to apoptotic signalling.
A peptide eased signs of aging in heart cells damaged by a cancer drug
Researchers treated heart muscle cells in a dish with a cancer drug, then a peptide called SS-31. The peptide reduced several signs of aging, but not cell cycle arrest. This was done only in lab cells, so it does not show the peptide would help people.
Two drugs together eased stroke brain damage in mice
Researchers gave mice two compounds, alone and together, after a stroke-like injury to the brain. The mice given both had less brain damage and better nerve function than those given either one alone.
Peptide SS-31 eased radiation-caused aging signs in heart cells
Researchers exposed heart cells to radiation and gave some of them SS-31. SS-31 reduced several aging signs, but this was only tested in cells, not people.
Two mitochondria-targeted drugs studied in aged female mice with fatty liver disease
Researchers gave two drugs to older mice with fatty liver disease caused by a rich diet. Both drugs improved liver markers in the mice, but this does not show they would help people.
The Oxidative-Mitochondrial-Inflammatory Axis in Retinitis Pigmentosa: Extracellular mtDNA as Biomarker and Therapeutic Read-Out.
Retinitis pigmentosa (RP) is the most common inherited retinal dystrophy (prevalence ~1:4000) and a leading Mendelian cause of working-age blindness.
See all research on Elamipretide (SS-31) →